ArticleNature communications2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Article
- Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma.International journal of molecular sciences · 2026Review
- Advances in immune microenvironment profiling during multiple myeloma progression and therapy.International journal of hematology · 2026Review
- Elevated Allele Frequency of a Common GermlineCancers · 2026Article
- A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.Blood cancer journal · 2026Article
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.Nature communications · 2026Article
- Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response.Blood neoplasia · 2026Article
- Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.Frontiers in immunology · 2026Review
- Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.Blood advances · 2025Article
- Elevated Allele Frequency and Male-Predominance of a CommonCurrent issues in molecular biology · 2025Article
- TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.Oncoimmunology · 2025Article
- CyTOF profiling of bone marrow immune dynamics across myeloma stages.Oncoimmunology · 2025Article
- Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies.Haematologica · 2025Article
- Review
- Article
- T cell phenotype and clonality changes in myeloma patients with short overall survival.JCI insight · 2025Article
- Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management.The EPMA journal · 2025Review
- Comparative analysis of the performance of the large language models ChatGPT-3.5, ChatGPT-4 and Open AI-o1 in the field of Programmed Cell Death in myeloma.Discover oncology · 2025Article
- T-lymphocytes suppression by CD14Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 4 countries.
Cirino Botta *Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy. cirino.botta@unipa.it.ORCID http://orcid.org/0000-0002-1522-4504
Cristina Perez *Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0003-3586-2666
Marta LarrayozClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0001-6097-8244
Noemi PuigHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.
Maria-Teresa CedenaHospital Universitario 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.ORCID http://orcid.org/0000-0001-5851-3720
Rosalinda TerminiClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
Ibai GoicoecheaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0002-5329-2225
Sara RodriguezClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0001-6509-0447
Aintzane ZabaletaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
Aitziber LopezClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
Sarai SarvideClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
Laura BlancoClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
Daniele M PapettiDepartment of Informatics, Systems and Communication, University of Milano-Bicocca, Milan, Italy.ORCID http://orcid.org/0000-0002-3574-6027
Marco S NobileDepartment of Environmental Sciences, Informatics and Statistics, Ca' Foscari University of Venice, Venice, Italy.ORCID http://orcid.org/0000-0002-7692-7203
Daniela BesozziDepartment of Informatics, Systems and Communication, University of Milano-Bicocca, Milan, Italy.ORCID http://orcid.org/0000-0001-5532-3059
Massimo GentileDepartment of Oncohematology, "Annunziata" Hospital, Cosenza, Italy.
Pierpaolo CorrealeMedical Oncology Unit, Great Metropolitan Hospital "Riuniti" of Reggio Calabria, Reggio Calabria, Italy.
Sergio SiragusaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Albert OriolInstitut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain.
Maria Esther González-GarciaServicios de Medicina Interna y Hematología, Hospital de Cabueñes, Gijón, Asturias, Spain.
Anna SuredaInstitut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Felipe de ArribaHospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
Rafael Rios TamayoHospital Universitario Puerta de Hierro, Majadahonda, Spain.ORCID http://orcid.org/0000-0001-8193-1402
Jose-Maria MoraledaHospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.ORCID http://orcid.org/0000-0001-9080-1466
Mercedes GironellaHospital Vall d'Hebron, Barcelona, Spain.
Miguel T HernandezHospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Joan BargayHospital Son Llatzer, Palma de Mallorca, Spain.
Luis PalomeraHospital Clínico Lozano Blesa, Zaragoza, Spain.
Albert Pérez-MontañaHospital Son Espases, Palma de Mallorca, Spain.
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0961-0035
Hervé Avet-LoiseauUnite de Genomique du Myelome, IUC-T Oncopole, Toulouse, France.
Aldo RoccaroDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia, BS, Italy.ORCID http://orcid.org/0000-0002-1872-5128
Alberto OrfaoCancer Research Center (IBMCC-CSIC/USAL-IBSAL), CIBER-ONC number CB16/12/00400, Salamanca, Spain.ORCID http://orcid.org/0000-0002-0007-7230
Joaquin Martinez-LopezHospital Universitario 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.
Laura RosiñolHospital Clínic IDIBAPS, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2534-9239
Juan-José LahuertaHospital Universitario 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.ORCID http://orcid.org/0000-0002-3393-9570
Joan BladeHospital Clínic IDIBAPS, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4563-3405
Maria-Victoria MateosHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.ORCID http://orcid.org/0000-0003-2390-1218
Jesús F San-MiguelClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0002-9183-4857
Jose-Angel Martinez ClimentClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0002-7938-3950
Bruno PaivaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain. bpaiva@unav.es.ORCID http://orcid.org/0000-0003-1977-3815
Programa Para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) cooperative group
iMMunocell study group
Navarre Institute of Health Research · ESHospital Universitario 12 De Octubre · ESHospital Clínic de Barcelona · ESHospital General Universitario Morales Meseguer · ESInstituto de Investigación Biomédica de Salamanca · ESAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCa' Foscari University of Venice · ITClinica Universidad de Navarra · ESDepartment of Health · ESHeidelberg University · DEHospital Clínico Universitario Lozano Blesa · ESHospital Son Llatzer · ESHospital Universitario De Cabueñes · ESHospital Universitario de Canarias · ESHospital Universitario Puerta de Hierro Majadahonda · ESHospital Universitario Son Espases · ESInstitut Català d'Oncologia · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstitute of Molecular Bioimaging and Physiology · ITInstitut universitaire du cancer de Toulouse Oncopole · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed multiple immune checkpoints, suggesting a potentially dysfunctional phenotype. Dual targeting of PD-1 + LAG3 or PD-1 + TIGIT partially restored their function in mice with MM. We identify phenotypic hallmarks of large intratumoral T cell clones, and demonstrate that the CD27
Indexed as
Multiple MyelomaAdultAnimalsClone CellsHumansLenalidomideMiceProgrammed Cell Death 1 ReceptorT-LymphocytesLenalidomideProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.